Literature DB >> 26004577

Synthesis and structure-activity relationships of novel cationic lipids with anti-inflammatory and antimicrobial activities.

Melissa Myint1, Robert Bucki2, Paul A Janmey3, Scott L Diamond4.   

Abstract

Certain membrane-active cationic steroids are known to also possess both anti-inflammatory and antimicrobial properties. This combined functionality is particularly relevant for potential therapies of infections associated with elevated tissue damage, for example, cystic fibrosis airway disease, a condition characterized by chronic bacterial infections and ongoing inflammation. In this study, six novel cationic glucocorticoids were synthesized using beclomethasone, budesonide, and flumethasone. Products were either monosubstituted or disubstituted, containing one or two steroidal groups, respectively. In vitro evaluation of biological activities demonstrated dual anti-inflammatory and antimicrobial properties with limited cytotoxicity for all synthesized compounds. Budesonide-derived compounds showed the highest degree of both glucocorticoid and antimicrobial properties within their respective mono- and disubstituted categories. Structure-activity analyses revealed that activity was generally related to the potency of the parent glucocorticoid. Taken together, these data indicate that these types of dual acting cationic lipids can be synthesized with the appropriate starting steroid to tailor activities as desired.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory; Antimicrobial; Cationic lipids; Cystic fibrosis; Lipofection

Mesh:

Substances:

Year:  2015        PMID: 26004577      PMCID: PMC4459899          DOI: 10.1016/j.bmcl.2015.04.104

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

Review 1.  The bacterial cell envelope.

Authors:  Thomas J Silhavy; Daniel Kahne; Suzanne Walker
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-14       Impact factor: 10.005

2.  Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone.

Authors:  W E Regelmann; G R Elliott; W J Warwick; C C Clawson
Journal:  Am Rev Respir Dis       Date:  1990-04

3.  In vivo evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection.

Authors:  Melissa Myint; Maria P Limberis; Peter Bell; Suryanarayan Somanathan; Angela Haczku; James M Wilson; Scott L Diamond
Journal:  Hum Gene Ther       Date:  2014-09-22       Impact factor: 5.695

4.  Novel cationic lipids with enhanced gene delivery and antimicrobial activity.

Authors:  David E Fein; Robert Bucki; Fitzroy Byfield; Katarzyna Leszczynska; Paul A Janmey; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2010-06-23       Impact factor: 4.436

Review 5.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

6.  Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation.

Authors:  Oana Ciofu; Bente Riis; Tacjana Pressler; Henrik Enghusen Poulsen; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Binding kinetics of budesonide to the human glucocorticoid receptor.

Authors:  N Esmailpour; P Högger; P Rohdewald
Journal:  Eur J Pharm Sci       Date:  1998-07       Impact factor: 4.384

8.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Authors:  B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

9.  Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties.

Authors:  Claudia Grossmann; Tim Scholz; Marina Rochel; Christiane Bumke-Vogt; Wolfgang Oelkers; Andreas F H Pfeiffer; Sven Diederich; Volker Bahr
Journal:  Eur J Endocrinol       Date:  2004-09       Impact factor: 6.664

10.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

View more
  2 in total

Review 1.  Relevance of Lipid-Based Products in the Management of Dry Eye Disease.

Authors:  Jean-Sébastien Garrigue; Mourad Amrane; Marie-Odile Faure; Juha M Holopainen; Louis Tong
Journal:  J Ocul Pharmacol Ther       Date:  2017-09-28       Impact factor: 2.671

Review 2.  Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties.

Authors:  Angélique Mottais; Tony Le Gall; Yann Sibiril; Julian Ravel; Véronique Laurent; Frédérique d'Arbonneau; Tristan Montier
Journal:  Biosci Rep       Date:  2017-11-17       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.